Liver Transplant Rejection – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Liver Transplant Rejection – Pipeline Review, H2 2017’, provides an overview of the Liver Transplant Rejection pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Liver Transplant Rejection, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Liver Transplant Rejection and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Liver Transplant Rejection

The report reviews pipeline therapeutics for Liver Transplant Rejection by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Liver Transplant Rejection therapeutics and enlists all their major and minor projects

The report assesses Liver Transplant Rejection therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Liver Transplant Rejection

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Liver Transplant Rejection

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Liver Transplant Rejection pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Astellas Pharma Inc

Biogen Inc

Conatus Pharmaceuticals Inc

Dompe Farmaceutici SpA

RedHill Biopharma Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Liver Transplant Rejection - Overview

Liver Transplant Rejection - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Liver Transplant Rejection - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Liver Transplant Rejection - Companies Involved in Therapeutics Development

Astellas Pharma Inc

Biogen Inc

Conatus Pharmaceuticals Inc

Dompe Farmaceutici SpA

RedHill Biopharma Ltd

Liver Transplant Rejection - Drug Profiles

ABC-294640 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy for Liver Transplant Rejection - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy for Liver Transplantation - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy for Liver Transplantation - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

emricasan - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FX-06 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MDR-201 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MDR-202 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MDR-203 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MDR-204 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

reparixin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rituximab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tacrolimus - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TR-002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Triplex - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Liver Transplant Rejection - Dormant Projects

Liver Transplant Rejection - Discontinued Products

Liver Transplant Rejection - Product Development Milestones

Featured News & Press Releases

Nov 16, 2015: Conatus Pharmaceuticals Announces Poster Presentations at AASLD Annual Meeting

May 12, 2014: Conatus Pharmaceuticals Initiates Phase 2b Trial Targeting Fibrosis in Liver Transplant Recipients

Nov 02, 2013: Conatus Pharmaceuticals Presents Data Demonstrating Emricasan's Safety Profile at the AASLD Liver Meeting

Dec 04, 2009: Hikma signs new agreement for Advagraf with Astellas

Jun 23, 2008: Astellas submit an sNDA for the immunosuppressant Prograf for Ulcerative Colitis in Japan

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Liver Transplant Rejection, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Liver Transplant Rejection – Pipeline by Astellas Pharma Inc, H2 2017

Liver Transplant Rejection – Pipeline by Biogen Inc, H2 2017

Liver Transplant Rejection – Pipeline by Conatus Pharmaceuticals Inc, H2 2017

Liver Transplant Rejection – Pipeline by Dompe Farmaceutici SpA, H2 2017

Liver Transplant Rejection – Pipeline by RedHill Biopharma Ltd, H2 2017

Liver Transplant Rejection – Dormant Projects, H2 2017

Liver Transplant Rejection – Discontinued Products, H2 2017

List of Figures

List of Figures

Number of Products under Development for Liver Transplant Rejection, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports